Go to deals
Energy

CVA EOS Srl has completed a mandatory public tender offer on Renergetica SpA

February 2024 — CVA EOS Srl has acquired Renergetica SpA.

CVA EOS is a company operating in the wind and photovoltaic sector, wholly owned by CVA SpA (Compagnia Valdostana delle Acque).

Headquartered in Italy, Renergetica is a listed entity that designs engineering solutions for the renewable energy sector. The company specializes in the development of renewable energy plants, hybrid power generation systems and hybrid grids.

Our role in the transaction

Oaklins Italy’s parent company Banca Akros acted as the financial advisor to CVA EOS and appointed broker in the collection of shares in the total mandatory public tender offer of 17.8% of Renergetica SpA by CVA EOS Srl.

Parties

Talk to the deal team

Giulio Greco

Managing Director
Milan, Italy
Oaklins Italy

Marco Valsecchi

Associate
Milan, Italy
Oaklins Italy

Rita Vizzi

Associate
Milan, Italy
Oaklins Italy

Related deals

Alba has completed a voluntary public tender offer for the shares of Borgosesia
Real Estate

Alba has completed a voluntary public tender offer for the shares of Borgosesia

Alba S.r.l. has completed a voluntary public tender offer for 100% of the shares of Borgosesia S.p.A.

Learn more
GVS has completed a voluntary partial tender offer for its own shares
Industrial Machinery & Components

GVS has completed a voluntary partial tender offer for its own shares

GVS S.p.A. has completed a voluntary partial public tender offer for 12.3% of its own share capital.

Learn more
Nexxtlab has successfully raised funding to support its growth
Energy

Nexxtlab has successfully raised funding to support its growth

Nexxtlab, a Luxembourg-based energy technology company, has raised growth capital from an experienced international energy player. The investment marks an important milestone in Nexxtlab’s development and will support the company’s commercial expansion across Europe, continued product innovation and the further scaling of its energy management platform.

Learn more